Nu-V3 Neuromodulation Therapy
Nu-V3 non-invasive neuromodulation therapy stimulates the peripheral auricular (ear) nerves through a safe, generated ‘pulsed’ micro-current signal with a device that is placed on the outside of the ear resulting in cranial nerve stimulation which in turn can help mitigate the symptoms of pain, anxiety, depression, and sleeplessness.
Nu-V3’s micro-signal sent to the cranial nerves of the Autonomic Nervous System (ANS), including the vagus nerve, assists it to regain the proper balance between the sympathetic and parasympathetic systems. This in turn also may result in:
- Release of endorphins
- Increased Blood Flow
- Implanted stimulator at site of treatment
- Immune system rebalance and decreased inflammation
- Pacemaker at site of treatment
- Use of photosensitive medications
- Active Cancer at the site of treatment
- Bleeding at the site of treatment
- Recent onset of cardiac issue
Please note that Nu-V3 therapy is currently investigational and not FDA cleared and may become available in 2021.
To learn more, please visit Nu-V3.com.
Autonomic Nervous System Dysfunction
Antecedent factors can also play a role in the development of central sensitization. The onset of pain is often associated with subsequent development of conditions such as depression, insomnia, fear-avoidance, anxiety and other stressors. The stress of these responses can, in turn, further exacerbate the reactivity of the nervous system, leading to central sensitization.
Nu-V3 therapy can help “wind-down” the nervous and treat CSS.
- Device lasts up to 30 days
- Device is non-invasive and does not require continuous treatment
- Significant relief can last for months without further treatments after completion of the treatment program
Who specializes in offering Nu-V3 therapy at GCSP?
Currently Nu-V3 therapy may become available in 2024 and is only offered under the direction of Dr. Kamran Chaudhary. For more information or to see if you may qualify for treatment when available, please schedule a consultation with Dr. Chaudhary.